Literature DB >> 12592388

Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).

Yutaka Masuda1, Ayano Nishida, Kouichi Hori, Takahiro Hirabayashi, Sachiko Kajimoto, Shigeo Nakajo, Takeshi Kondo, Masahiro Asaka, Kazuyasu Nakaya.   

Abstract

beta-Hydroxyisovalerylshikonin (beta-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in beta-HIVS-induced apoptotic process, we performed cDNA array analysis and found that beta-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10(-6) M beta-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by beta-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both beta-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, beta-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the beta-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592388     DOI: 10.1038/sj.onc.1206200

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Hinesol, a compound isolated from the essential oils of Atractylodes lancea rhizome, inhibits cell growth and induces apoptosis in human leukemia HL-60 cells.

Authors:  Yutaka Masuda; Takayuki Kadokura; Maki Ishii; Kimihiko Takada; Junichi Kitajima
Journal:  J Nat Med       Date:  2015-04-02       Impact factor: 2.343

3.  SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.

Authors:  Jun Li; Mingjia Tan; Ling Li; Deepika Pamarthy; Theodore S Lawrence; Yi Sun
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

4.  Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.

Authors:  Gina Chun; Dongsoon Bae; Kristen Nickens; Travis J O'Brien; Steven R Patierno; Susan Ceryak
Journal:  Carcinogenesis       Date:  2010-01-20       Impact factor: 4.944

5.  Polo-like kinase 1 (PLK1) is involved in toll-like receptor (TLR)-mediated TNF-α production in monocytic THP-1 cells.

Authors:  Jinyue Hu; Guihua Wang; Xueting Liu; Lina Zhou; Manli Jiang; Li Yang
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

6.  Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.

Authors:  Xiaoyue Zhao; Yanan Zhu; Jianhua Hu; Longwei Jiang; Limin Li; Shaochang Jia; Ke Zen
Journal:  Sci Rep       Date:  2018-09-28       Impact factor: 4.379

7.  Shikonin Inhibits the Proliferation of Human Breast Cancer Cells by Reducing Tumor-Derived Exosomes.

Authors:  Yao Wei; Mingzhen Li; Shufang Cui; Dong Wang; Chen-Yu Zhang; Ke Zen; Limin Li
Journal:  Molecules       Date:  2016-06-16       Impact factor: 4.411

8.  β-Hydroxyisovalerylshikonin regulates macrophage polarization via the AMPK/Nrf2 pathway and ameliorates sepsis in mice.

Authors:  Tao Pan; Yabin Chang; Min He; Zehui He; Jun Jiang; Xinling Ren; Fang Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

9.  Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.

Authors:  Hao Wu; Jiansheng Xie; Qiangrong Pan; Beibei Wang; Danqing Hu; Xun Hu
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

10.  Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor.

Authors:  Soon Young Jang; Eun Hyang Jang; Seo Young Jeong; Jong-Ho Kim
Journal:  Int J Oncol       Date:  2014-02-20       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.